They utilized an IL15Rα-IL15-encoding OV as the T-cell activating stimulus and a prostaglandin synthesis inhibitor as the anti-immunosuppressant, together with ACT of tumor-specific T cells. The gene discussed is IL15; the disease is neoplasm.